Hodgkin's Lymphoma References

REFERENCES

American Cancer Society. Hodgkin lymphoma. American Cancer Society website. http://www.cancer.org/acs/groups/cid/documents/webcontent/003105-pdf.pdf. 2014.
Bartlett NL, Foyil KV. Hodgkin lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier; 2014:2018-2032.e4.
Das P, Ng A, Constine LS, et al. ACR Appropriateness Criteria® on Hodgkin’s lymphoma-favorable prognosis stage I and II. American College of Radiology website. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/HodgkinsLymphomaFavorablePrognosisStageIAndII.pdf. 2011.
Eichenauer DA, Engert A, André M, et al; ESMO Guidelines Working Group. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25(Suppl 3):iii70-iii75. https://annonc.oxfordjournals.org/content/25/suppl_3/iii70.full.pdf. PMID: 25185243
Eichenauer DA, Engert A, Diehl V. Hodgkin lymphoma. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weltz JI, Anastasi J. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA; 2013:1138-1156.
Follows GA, Ardeshna KM, Barrington SF, et al; British Committee for Standards in Haematology. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):34-49. http://onlinelibrary.wiley.com/doi/10.1111/bjh.12878/epdf. PMID: 24712411
German Hodgkin Study Group. Hodgkin lymphoma. GHSG website. https://en.ghsg.org/disease-stages. 2016.
Hernandez-Ilizaliturri FJ. Hodgkin lymphoma treatment protocols. Medscape website. http://emedicine.medscape.com/article/2006680-overview. Aug 2014.
Horwitz S, Yahalom J. Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma. UptoDate website. http://www.uptodate.com/contents/initial-treatment-of-advanced-stage-iii-iv-classical-hodgkin-lymphoma?source=related_link. Aug 2015.
Jaffe ES, Pittaluga S, Anastasi J. Pathologic basis for the classification of non-hodgkin and hodgkin lymphomas. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weltz JI, Anastasi J. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA; 2013:1112-1129.e2.
Mauch PM, Aster JC, LaCasce AS. Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma. UptoDate website. http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-nodular-lymphocyte-predominant-hodgkin-lymphoma?source=search_result&search=nodular+lymphocyte+predominant+hodgkin&selectedTitle=2~12. Nov 2014.
National Cancer Institute. Adult hodgkin lymphoma treatment-for health professionals (PDQ®). National Cancer Institute website. http://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq#section/all. Jan 2016.
National Cancer Institute. Childhood hodgkin lymphoma treatment-for health professionals (PDQ®). National Cancer Institute website. http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq#section/all. Jan 2016.
National Cancer Institute. Drugs approved for hodgkin lymphoma. National Cancer Institute website. http://www.cancer.gov/about-cancer/treatment/drugs/hodgkin-lymphoma. Sep 2014.
National Comprehensive Cancer Network Hodgkin Lymphoma Panel. NCCN Clinical practice guidelines in oncology (NCCN Guidelines): Hodgkin lymphoma. Version 2.2015. NCCN website. http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. 2015.
Roberts KB, Younes A, Hodgson DC, et al. ACR Appropriateness Criteria® on Hodgkin’s lymphoma-unfavorable clinical stage I and II. American College of Radiology website. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/HodgkinsLymphomaUnfavorableClinicalStageIAndII.pdf. 2015.
Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Oct 26, 2015. Clin Transl Oncol. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689754/pdf/12094_2015_Article_1429.pdf. PMID: 26497354
Sweetman SC, Blake PS, Brayfield A, et al, eds. Martindale: The complete drug reference. MedicinesComplete website. https://www.medicinescomplete.com/mc/martindale/current/. 2016.
Terezakis SA, Metzger ML, Constine LS, et al. ACR Appropriateness Criteria® on pediatric Hodgkin’s lymphoma. American College of Radiology website. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/PediatricHodgkinLymphoma.pdf. 2012.
Wilder RB, Ng A, Constine LS, et al. ACR Appropriateness Criteria® on Hodgkin’s lymphoma-stage III and IV. American College of Radiology website. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/HodgkinsLymphomaStageIIIAndIV.pdf. 2010.
Canellos GP. Overview of the treatment of classic Hodgkin lymphoma in adults. UpToDate. www.uptodate.com.. 15 Feb 2019.
LaCasce AS. Treatment of relapsed or refractory classic Hodgkin lymphoma. UpToDate. www.uptodate.com. 12 Sep 2018.
LaCasce AS, Ng AK. Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma. UpToDate. www.uptodate.com. 31 May 2019.
National Comprehensive Cancer Network. Hodgkin's lymphoma. version 2.2019. NCCN. www.nccn.com. 15 Jul 2019.
National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: Hodgkin lymphoma version 2.2020. NCCN. https://www.nccn.org. 17 Apr 2020. Accessed 13 May 2020.
Cancer Therapy Advisor. Hodgkin lymphoma treatment regimens. Cancer Therapy Advisor. https://www.cancertherapyadvisor.com/. 01 Jan 2020.
Dhakal S, Advani R, Ballas LK, et al; Expert Panel on Radiation Oncology – Lymphoma. ACR Appropriateness Criteria® Hodgkin lymphoma - favorable prognosis stage I and II. Am J Clin Oncol. 2016 Dec;39(6):535-544. doi: 10.1097/COC.0000000000000331. PMID: 27643717
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hodgkin lymphoma. Version 4.2021. NCCN. https://www.nccn.org/. 20 Apr 2021.
Cancer Therapy Advisor. Hodgkin lymphoma treatment regimens. Cancer Therapy Advisor. https://www.cancertherapyadvisor.com/. Jan 2020.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Hodgkin lymphoma. Version 2.2022. NCCN. https://www.nccn.org/. Feb 2022.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).

Carfilzomib-based triplet regimen a potential upfront treatment for high-risk MM

Pearl Toh, 22 Oct 2020

The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.